Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease

Brain Pathology

Volumn 22, Issue 5, 2012, Pages 636-653

  Aso, Ester ^a   Lomoio, Selene ^a,b   Lõpez González, Irene ^a   Joda, Laura ^a   Carmona, Margarita ^a   Fernández Yagüe, Núria ^a   Moreno, Jesús ^a   Juvés, Salvador ^a   Pujol, Aurora ^c   Pamplona, Reinald ^d   Portero Otin, Manuel ^d   Martín, Virginia ^e   Díaz, Mario ^e   Ferrer, Isidro ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF PAVIA   (Italy)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d UNIVERSITY OF LLEIDA   (Spain)

^e UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

synuclein; amyloid; Alzheimer's disease; APP PS1 transgenic mice; mitochondria; oxidative stress; synapses; tau phosphorylation; ubiquitin proteasome system

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; IMMUNOPROTEASOME; PRESENILIN 1; PROTEASOME; TAU KINASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FAMILIAL ALZHEIMER DISEASE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION;

AGE FACTORS; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; AVOIDANCE LEARNING; BRAIN; COGNITION DISORDERS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, IMMUNOELECTRON; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEUROPSYCHOLOGICAL TESTS; PLAQUE, AMYLOID; PRESENILIN-1; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOGNITION (PSYCHOLOGY); RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TAU PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84865516784     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00560.x     Document Type: Article

References (71)

1. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al, (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281: 29739-29752. (Pubitemid 44536983)
2. Bettens K, Sleegers K, Van Broeckhoven C, (2010) Current status of Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19: R4-R11.
3. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, et al, (2003) Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 184: 247-263. (Pubitemid 37444035)
4. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al, (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013. (Pubitemid 26424026)
5. Botchler M, Ditzel Groll M, Hartmann C, Huber R, (1999) The proteasome. Annu Rev Biophys Biomol Struct 28: 295-317. (Pubitemid 29319261)
6. Braak H, Braak E, (1998) Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm 53: 127-110.
7. Brion JP, Couck AM, Bruce M, Anderton B, Flament-Durand J, (1991) Synaptophysin and chromogranin A immunoreactivities in senile plaques of Alzheimer's disease. Brain Res 539: 143-150.
8. Büttner A, Rohrmoser K, Mall G, Penning R, Weis S, (2006) Widespread axonal damage in the brain of drug abusers as evidenced by accumulation of beta-amyloid precursor protein (β-APP): an immunohistochemical investigation. Addiction 101: 1339-1346. (Pubitemid 44199526)
9. Cai Y, Xiong K, Zhang XM, Cai H, Luo XG, Feng JC, et al, (2010) β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and beta-amyloid accumulation. Eur J Neurosci 32: 1223-1238.
10. Cecarini V, Ding Q, Keller JN, (2007) Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 41: 673-680. (Pubitemid 46845588)
11. Dolan PJ, Johnson GV, (2010) The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel 13: 595-603.
12. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ, (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl) 104: 7-11. (Pubitemid 36075353)
13. Ferrer I, (2004) Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox Res 6: 469-475.
14. Ferrer I, Martí E, Tortosa A, Blasi J, (1998) Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol 57: 218-225. (Pubitemid 28125501)
15. Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20. (Pubitemid 38200585)
16. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfõ E, Avila J, (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2: 3-18. (Pubitemid 41389255)
17. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC, (2004) Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164: 719-125.
18. Glickman MH, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428. (Pubitemid 34654457)
19. Gong B, Leznik E, (2007) The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20: 365-370. (Pubitemid 350219068)
20. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Muller WE, (2006) Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. FASEB J 19: 2040-2041.
21. Herschko A, Ciechanover A, (1998) The ubiquitin system. Annu Rev Biochem 67: 425-479. (Pubitemid 28411135)
22. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al, (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023. (Pubitemid 32323483)
23. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G, (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51: 783-786. (Pubitemid 34568861)
24. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, et al, (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 100: 802-809. (Pubitemid 46095629)
25. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I, (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (Berl) 118: 53-69.
26. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ, (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108: 5819-5824.
27. Keller JN, Hanni KB, Markesbery WR, (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439. (Pubitemid 30418211)
28. Kidd M, (1964) Alzheimer's disease: an electron microscopical study. Brain 87: 307-320.
29. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, et al, (1992) Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59: 776-779.
30. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM, (2004) Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation. Exp Neurol 187: 279-288. (Pubitemid 38610274)
31. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al, (2010) Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 29: 3408-3420.
32. Lang T, Jahn R, (2008) Core proteins of the secretory machinery. Handb Exp Pharmacol 184: 107-127.
33. Larsen CN, Price JS, Wilkinson KD, (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35: 6735-6744. (Pubitemid 26172432)
34. Li J, Rechsteiner M, (2001) Molecular dissection of the 11S REG (PA28) proteasome activators. Biochimie 83: 373-383. (Pubitemid 32293660)
35. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al, (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101: 3632-3637. (Pubitemid 38338246)
36. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG, (2010) Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem 285: 27737-27744.
37. Lu Y, Li T, Qureshi HY, Han D, Paudel HK, (2011) Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain. J Biol Chem 286: 20569-20581.
38. Luse SA, Smith KR Jr, (1964) The ultrastructure of senile plaques. Am J Pathol 44: 553-563.
39. Marwarha G, Dasari B, Prabhakara JP, Schommer J, Ghribi O, (2010) β-Amyloid regulates leptin expression and tau phosphorylation through the mTORC1 signaling pathway. J Neurochem 115: 373-384.
40. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, et al, (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 282: 26326-26334. (Pubitemid 47443774)
41. Miners JC, Barua N, Kehoe PG, Gill S, Love S, (2011) Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70: 944-959.
42. Mohamed A, Cortez L, de Chaves EP, (2011) Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide. Curr Protein Pept Sci 12: 235-257.
43. Moreira PI, Santos MS, Oliveira CR, (2007) Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 9: 1621-1630. (Pubitemid 47462966)
44. Morrison JH, Hof PR, (2002) Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res 136: 467-486. (Pubitemid 35461000)
45. Muntané G, Dalfõ E, Martinez A, Ferrer I, (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related α-synucleinopathies. Neuroscience 152: 913-923.
46. Mustafiz T, Portelius E, Gustavsson MK, Hölttä M, Zetterberg H, Blennow K, et al, (2011) Characterization of the brain β-amyloid isoform pattern at different ages of Tg2576 mice. Neurodegener Dis 8: 352-363.
47. Mutisya EM, Bowling AC, Beal MF, (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63: 2179-2184. (Pubitemid 24369993)
48. Oddo S, (2008) The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 12: 363-373. (Pubitemid 351555121)
49. Pérez-Gracia E, Torrejõn-Escribano B, Ferrer I, (2008) Dystrophic neurites of senile plaques in Alzheimer's disease are deficient in cytochrome C oxidase. Acta Neuropathol (Berl) 116: 261-268.
50. Piccini A, Zanusso G, Borghi R, Noviello C, Monaco S, Russo R, et al, (2007) Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch Neurol 64: 738-745. (Pubitemid 46789842)
51. Pooler AM, Hanger DP, (2010) Functional implications of the association of tau with the plasma membrane. Biochem Soc Trans 38: 1012-1015.
52. Puig B, Gõmez-Isla T, Ribé E, Cuadrado M, Torrejõn-Escribano B, Dalfõ E, Ferrer I, (2004) Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30: 491-502. (Pubitemid 39423036)
53. Rudrabhatla P, Pant HC, (2011) Role of protein phosphatase 2A in Alzheimer's disease. Curr Alzheimer Res 8: 623-632.
54. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, et al, (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-617. (Pubitemid 40332718)
55. Sepulveda-Falla D, Matschke J, Bernreuther C, Hagel C, Puig B, Villegas A, et al, (2011) Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol 21: 452-463 [Epub ahead of print; doi:10.1111/j.1750-3639.2010.00469.x].
56. Steiner H, (2008) The catalytic core of gamma-secretase: presenilin revisited. Curr Alzheimer Res 5: 147-157. (Pubitemid 351536339)
57. Tamagno E, Bardini P, Guglielmotto M, Danni O, Tabaton M, (2006) The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic Biol Med 41: 202-212. (Pubitemid 43928492)
58. Terry RD, Gonatas NK, Weiss M, (1964) Ultrastuctural studies in Alzheimer's presenile dementia. Am J Pathol 44: 269-297.
59. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM, (2008) Aβ inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29: 1607-1618.
60. Varghese M, Zhao W, Wang J, Cheng A, Qian X, Chaudhry A, et al, (2011) Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD mice. Transl Neurosci 2: 1-5.
61. Venugopal C, Demos CM, Rao KS, Pappolla MA, Sambamurti K, (2008) β-secretase: structure, function, and evolution. CNS Neurol Disord Drug Targets 7: 278-294.
62. Vnek N, Rothblat LA, (1996) The hippocampus and long-term object memory in the rat. J Neurosci 16: 2780-2787. (Pubitemid 26122692)
63. Voges D, Zwickl P, Baumeister W, (1999) The 26 S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068. (Pubitemid 29449214)
64. Wallace DC, Fan W, (2010) Energetics, epigenetics, mitochondrial genetics. Mitochondrion 10: 12-31.
65. Walsh DM, Selkoe DJ, (2007) Aβ oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
66. Waxman EA, Giasson BI, (2011) Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 31: 7604-7618.
67. Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer TA, (2006) Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol (Berl) 111: 312-319.
68. Woodruff-Pak DS, (2008) Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 15: 507-521.
69. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, et al, (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9: 3-4. (Pubitemid 36098241)
70. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD, (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106: 14670-14675.
71. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, et al, (2007) β-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 27: 3639-3649. (Pubitemid 46557686)